Non-myeloablative tolerogenic treatment with tyrphostins
CA 2450807 A1 · Owner: Hadasit Medical Research Services And Development Ltd. · Inventors: Gazit, Aviv; Morecki, Shoshana; Levitzki, Alexander
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of inducing immune tolerance in a first mammal to antigens of a second, non-syngeneic, mammal, is disclosed. The method is utilized to minimize graft rejection and/or reduce graft-versus-host diseases in transplantation procedures and to produce hematopoietic mixed chimeras. Methods of determining the activity of tyrphostins and the optimal concentration thereof in this method are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 16, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 16, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 16, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.